Gepirone
Brand names: Exxua · Active ingredient: Gepirone Hydrochloride
In short: EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults.
What is Gepirone used for?
EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults.
⚠ Boxed warning (FDA's strongest warning)
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors
. EXXUA is not approved for use in pediatric patients
Gepirone dosage
Electrocardiogram and Electrolyte Monitoring
Correct electrolyte abnormalities prior to initiating EXXUA. In patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia, also monitor electrolytes during dose titration and periodically during treatment with EXXUA
.
Perform an electrocardiogram (ECG) prior to initiating EXXUA, during dosage titration, and periodically during treatment.
Do not initiate EXXUA if QTc is > 450 msec at baseline.
Monitor ECGs more frequently if EXXUA is used:
concomitantly with drugs known to prolong the QT interval
in patients who develop QTc ≥ 450 msec during treatment
in patients with a significant risk of developing torsade de pointes
.
Do not escalate the EXXUA dosage if the QTcF is > 450 msec
.
Bipolar Disorder, Mania, and Hypomania Screening
Screen patients for a personal or family history of bipolar disorder, mania, or hypomania prior to initiating treatment with EXXUA
.
Take EXXUA orally with food at approximately the same time each day
. Swallow tablets whole. Do not split, crush, or chew EXXUA.
The recommended starting dosage of EXXUA is 18.2 mg once daily. Based on clinical response and tolerability, the dosage may be increased to 36.3 mg orally once daily on Day 4 and further titrated to 54.5 mg orally once daily after Day 7 and to 72.6 mg orally once daily after an additional week. The maximum recommended daily dosage of EXXUA is 72.6 mg once daily.
The recommended starting dosage of EXXUA in geriatric patients is 18.2 mg orally once daily. Based on clinical response and tolerability, the dosage may be increased to maximum recommended dosage of 36.3 mg orally once daily after Day 7
.
The recommended starting dosage of EXXUA in patients with creatinine clearance < 50 mL/min is 18.2 mg orally once daily. Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 36.3 mg orally once daily after Day 7
.
The recommended dosage in patients with creatinine clearance ≥ 50 mL/min is the same as in patients with normal renal function
.
The recommended starting dose of EXXUA in patients with moderate (Child-Pugh B) hepatic impairment is 18.2 mg once daily. Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 36.3 mg orally once daily after Day 7
.
EXXUA is contraindicated in patients with severe (Child-Pugh C) hepatic impairment
.
The recommended dosage in patients with mild (Child-Pugh A) hepatic impairment is the same as patients with normal hepatic function.
Reduce the EXXUA dose by 50% when used concomitantly with a moderate CYP3A4 inhibitor
.
EXXUA is contraindicated in patients receiving strong CYP3A4 inhibitors
. …
How to take Gepirone — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidal ideation and behavior, especially during early treatment and when the dose is adjusted up or down and instruct them to report such symptoms to their healthcare provider
.
QT Prolongation
Inform patients to consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations
. Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or over-the-counter medications because there is an increased risk for drug interactions with EXXUA
.
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of EXXUA with SSRIs or tricyclic antidepressants. Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome
.
Activation of Mania or Hypomania
Advise patients to observe for signs of activation of mania or hypomania and instruct them to report such symptoms to their healthcare provider
. …
Warnings & precautions
Do not take this medicine if: EXXUA is contraindicated in patients:
with known hypersensitivity to gepirone or components of EXXUA
.
with prolonged QTc interval > 450 msec at baseline
.
with congenital long QT syndrome
.
receiving concomitant strong CYP3A4 inhibitors
.
with severe hepatic impairment
.
taking, or within 14 days of stopping, MAOIs due to the risk of serious and possibly fatal drug interactions, including hypertensive crisis and serotonin syndrome
. Starting EXXUA in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated.
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients aged 24 years and younger was greater than in placebo-treated patients.
There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in
Table 1. …
Gepirone side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Suicidal Thoughts and Behaviors in Adolescents and Young Adults
QT Prolongation
Serotonin Syndrome
Activation of Mania or Hypomania
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
During premarketing assessment, multiple doses of EXXUA were administered to 1,976 adult patients with major depressive disorder (MDD) in controlled phase 2 and 3 clinical studies, including 1,639 patients in placebo-controlled phase 2 and 3 trials in MDD, with 237 patients exposed for over six months. The population treated with EXXUA in the pooled placebo-controlled studies ranged from 15 to 78 years of age, was 34% male and 66% female, and was 80% Caucasian, 11% Black, and 9% other race.
The adverse reaction data below are based on two placebo-controlled, flexible-dose, clinical studies (Study 1, Study 2) in which either EXXUA 18.2 mg to 72.6 mg (n=226) or placebo (n=230) was administered to adult patients with MDD during an 8-week double-blind treatment period
. Study 1 had a median age of 39 years and were 61% female, 73% Caucasian, 9% Black, 2% Asian, and 16% Other (Hispanic or Native American). …
Drug interactions
Table 3displays clinically important drug interactions with EXXUA.
CYP3A4 Inhibitors
Clinical Impact | Strong CYP3A4 Inhibitors
Concomitant use of EXXUA with a strong CYP3A4 inhibitor increases EXXUA exposure by ~ 5-fold
.
Moderate CYP3A4 Inhibitors
Concomitant use with a moderate CYP3A4 inhibitor increases EXXUA exposure by ~ 2.6-fold
.
Intervention | Strong CYP3A4 Inhibitors
EXXUA is contraindicated in patients taking strong CYP3A4 inhibitors
[see
Dosage and Administration (2.7),
Contraindications (4), and
Warnings and Precautions (5.2)]
.
Moderate CYP3A4 Inhibitors
If EXXUA is used with a moderate CYP3A4 inhibitor, reduce the dosage of EXXUA
.
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact | Concomitant use of EXXUA with MAOIs increases the risk of serotonin syndrome.
Intervention | EXXUA is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue or in patients who have taken MAOIs within the preceding 14 days.
Allow at least 14 days after stopping EXXUA before starting an MAOI
[see
Dosage and Administration (2.8),
Contraindications (4), and
Warnings and Precautions (5.3)]. …
About this medicine
EXXUA contains gepirone, in the salt form as gepirone hydrochloride (HCl). The chemical name is 2,6- piperidinedione,4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, monohydrochloride. The molecular weight of gepirone HCl is 395.93 and the structural formula is as follows:
Gepirone HCl is a white to off-white crystalline powder, which is readily soluble in water.
EXXUA is supplied as extended-release tablets for oral administration. Each extended-release tablet contains 18.2 mg, 36.3 mg, 54.5 mg, or 72.6 mg, gepirone equivalent to 20 mg, 40 mg, 60 mg, or 80 mg of gepirone HCl respectively. The extended-release tablets also contain the following inactive ingredients: colloidal silicon dioxide, Hypromellose, iron oxide (red and/or yellow colorants), magnesium stearate, and microcrystalline cellulose.
How it works: The mechanism of the antidepressant effect of EXXUA is not fully understood but is thought to be related to its modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0c78edd8-6acb-433c-9d34-2527da8d64e1. Read the full official label on DailyMed.
Related medicines
Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone